Literature DB >> 1763432

Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

J Hardy1, D Allsop.   

Abstract

While there may be many causes of Alzheimer's disease (AD), the same pathological sequence of events, described here by John Hardy and David Allsop, is likely to occur in all cases. The recent discovery of a pathogenic mutation in the beta-amyloid precursor protein (APP) gene on chromosome 21 suggests that APP Mismetabolism and beta-amyloid deposition are the primary events in the disease process. The occurrence of AD in Down syndrome is consistent with this hypothesis. The pathological cascade for the disease process is most likely to be: beta-amyloid deposition----tau phosphorylation and tangle formation----neuronal death. The development of a biochemical understanding of this pathological cascade will facilitate rational design of drugs to intervene in this process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763432     DOI: 10.1016/0165-6147(91)90609-v

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  662 in total

Review 1.  Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.

Authors:  Ernesto Solis; Kevin N Hascup; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer's disease.

Authors:  Ai-Wu Xiao; Jing He; Qian Wang; Yi Luo; Yan Sun; Yan-Ping Zhou; Yang Guan; Paul J Lucassen; Jia-Pei Dai
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

3.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 4.  Alzheimer's disease.

Authors:  M Rossor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

5.  Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.

Authors:  Takashi Mori; Naoki Koyama; Jun Tan; Tatsuya Segawa; Masahiro Maeda; Terrence Town
Journal:  J Biol Chem       Date:  2017-05-16       Impact factor: 5.157

6.  Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease.

Authors:  A Parachikova; C W Cotman
Journal:  Neurobiol Dis       Date:  2007-07-10       Impact factor: 5.996

Review 7.  An emerging concept of prion infections as a form of transmissible cerebral amyloidosis.

Authors:  Omar Lupi; Marcius Achiame Peryassu
Journal:  Prion       Date:  2007 Oct-Dec       Impact factor: 3.931

8.  Leptin signaling and Alzheimer's disease.

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain.

Authors:  Li-Ming Wang; Qi Wu; Ryan A Kirk; Kevin P Horn; Ahmed H Ebada Salem; John M Hoffman; Jeffrey T Yap; Joshua A Sonnen; Rheal A Towner; Fernando A Bozza; Rosana S Rodrigues; Kathryn A Morton
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

10.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells.

Authors:  B D Gitter; L M Cox; R E Rydel; P C May
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.